Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 492


Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.

McCoach CE, Le A, Gowan K, Jones KL, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.

Clin Cancer Res. 2018 Apr 10. pii: clincanres.2452.2017. doi: 10.1158/1078-0432.CCR-17-2452. [Epub ahead of print]


Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).

Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA Jr.

Cancer. 2018 Mar 26. doi: 10.1002/cncr.31313. [Epub ahead of print]


Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.

Helfrich BA, Gao D, Bunn PA Jr.

Lung Cancer. 2018 Apr;118:148-154. doi: 10.1016/j.lungcan.2018.02.001. Epub 2018 Feb 4.


The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators.

Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.


Small-cell lung cancer: what we know, what we need to know and the path forward.

Gazdar AF, Bunn PA, Minna JD.

Nat Rev Cancer. 2017 Nov 10;17(12):765. doi: 10.1038/nrc.2017.106. [Epub ahead of print]


Advances in lung cancer.

Pacheco JM, Dimou A, Bunn PA.

Oncotarget. 2017 Sep 13;8(45):78247-78248. doi: 10.18632/oncotarget.20854. eCollection 2017 Oct 3. No abstract available.


Small-cell lung cancer: what we know, what we need to know and the path forward.

Gazdar AF, Bunn PA, Minna JD.

Nat Rev Cancer. 2017 Dec;17(12):725-737. doi: 10.1038/nrc.2017.87. Epub 2017 Oct 27. Review. Erratum in: Nat Rev Cancer. 2017 Nov 10;:.


Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.

Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS.

Anticancer Drugs. 2017 Nov;28(10):1086-1096. doi: 10.1097/CAD.0000000000000545.


Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.

Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR.

J Thorac Oncol. 2018 Jan;13(1):134-138. doi: 10.1016/j.jtho.2017.08.005. Epub 2017 Aug 24.


Robert Comis, MD, The Passing of a "Lung Man".

Bunn PA Jr.

J Thorac Oncol. 2017 Aug;12(8):1323-1324. doi: 10.1016/j.jtho.2017.06.014. No abstract available.


HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR.

Cancer. 2017 Nov 1;123(21):4099-4105. doi: 10.1002/cncr.30869. Epub 2017 Jul 25.


Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.

Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV.

Lung Cancer. 2017 Feb;104:45-51. doi: 10.1016/j.lungcan.2016.12.007. Epub 2016 Dec 12.


Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016.

Bunn PA Jr.

J Clin Oncol. 2017 Jan 10;35(2):243-252. Epub 2016 Nov 7. No abstract available.


KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer.

He Y, Bunn PA, Zhou C, Chan D.

Oncotarget. 2016 Dec 13;7(50):82104-82111. doi: 10.18632/oncotarget.13486.


AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J.

Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23.


Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):27-35. doi: 10.1016/j.jtho.2016.09.003. Epub 2016 Sep 15. Review.


New and emerging targeted treatments in advanced non-small-cell lung cancer.

Hirsch FR, Suda K, Wiens J, Bunn PA Jr.

Lancet. 2016 Sep 3;388(10048):1012-24. doi: 10.1016/S0140-6736(16)31473-8. Epub 2016 Sep 1. Review.


Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.

Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA Jr.

Mol Cancer Ther. 2016 Oct;15(10):2314-2322. Epub 2016 Aug 5.


The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.


Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.

Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC.

Lung Cancer. 2016 Jun;96:27-32. doi: 10.1016/j.lungcan.2016.03.007. Epub 2016 Mar 26.


Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-38. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.


Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.


Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer.

Bunn PA Jr, Gaspar LE, Weyant MJ, Mitchell JD.

Cancer. 2016 Mar 1;122(5):674-5. doi: 10.1002/cncr.29797. Epub 2015 Dec 23. No abstract available.


Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.

Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS.

Cancer. 2016 Mar 1;122(5):766-72. doi: 10.1002/cncr.29812. Epub 2015 Dec 22.


Adjuvant TKIs in NSCLC: what can we learn from RADIANT?

Hirsch FR, Bunn PA Jr.

Nat Rev Clin Oncol. 2015 Dec;12(12):689-90. doi: 10.1038/nrclinonc.2015.202. Epub 2015 Nov 10. No abstract available.


Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.

Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA.

Cancer Prev Res (Phila). 2016 Jan;9(1):96-104. doi: 10.1158/1940-6207.CAPR-15-0305. Epub 2015 Nov 5.


Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR.

Oncologist. 2015 Oct;20(10):1175-81. doi: 10.1634/theoncologist.2015-0114. Epub 2015 Sep 1.


Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers.

Bunn PA Jr, Kim ES.

Clin Lung Cancer. 2015 Jul;16(4):245-51. doi: 10.1016/j.cllc.2015.02.008. Epub 2015 Mar 6.


Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.

Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators.

J Thorac Oncol. 2015 May;10(5):768-777. doi: 10.1097/JTO.0000000000000516.


Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA Jr, Peled N.

Oncologist. 2015 Mar;20(3):316-22. doi: 10.1634/theoncologist.2014-0389. Epub 2015 Feb 26.


Personalized one-two punches for lung cancer.

Scarborough HA, Bunn PA Jr, DeGregori J.

Cell Res. 2015 Mar;25(3):269-70. doi: 10.1038/cr.2014.168. Epub 2014 Dec 30.


Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R.

J Clin Oncol. 2014 Dec 1;32(34):3824-30. doi: 10.1200/JCO.2014.56.7412. Epub 2014 Oct 27.


Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG.

Cancer. 2015 Feb 1;121(3):448-56. doi: 10.1002/cncr.29042. Epub 2014 Oct 1.


Reply to A. Braillon.

Johnson DH, Schiller JH, Bunn PA.

J Clin Oncol. 2014 Nov 1;32(31):3575. doi: 10.1200/JCO.2014.57.2545. Epub 2014 Sep 15. No abstract available.


"Companion diagnostics": has their time come and gone?

Hirsch FR, Bunn PA Jr, Herbst RS.

Clin Cancer Res. 2014 Sep 1;20(17):4422-4. doi: 10.1158/1078-0432.CCR-14-0932. Epub 2014 Jul 24.


Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA.

JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.


FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.


Is there clinical value to prognostic signatures in early-stage NSCLC?

Bunn PA Jr, Hirsch FR, Aisner DL.

Clin Cancer Res. 2014 Apr 1;20(7):1727-9. doi: 10.1158/1078-0432.CCR-13-3387. Epub 2014 Feb 28.


Recent clinical advances in lung cancer management.

Johnson DH, Schiller JH, Bunn PA Jr.

J Clin Oncol. 2014 Apr 1;32(10):973-82. doi: 10.1200/JCO.2013.53.1228. Epub 2014 Feb 24. Review. Erratum in: J Clin Oncol. 2014 May 10;32(14):1520. Dosage error in article text.


Progress in research on screening and genetics in lung cancer.

Hirsch FR, Bunn PA Jr.

Lancet Respir Med. 2014 Jan;2(1):19-21. doi: 10.1016/S2213-2600(13)70264-9. Epub 2013 Dec 23. No abstract available.


Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR.

J Thorac Oncol. 2013 Dec;8(12):e112-3. doi: 10.1097/JTO.0000000000000038. No abstract available.


Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC.

PLoS One. 2013 Dec 13;8(12):e82236. doi: 10.1371/journal.pone.0082236. eCollection 2013.


The evolution of tumor classification: a role for genomics?

Bunn PA Jr, Franklin W, Doebele RC.

Cancer Cell. 2013 Dec 9;24(6):693-4. doi: 10.1016/j.ccr.2013.11.019.


Lung cancer in 2013: state of the art therapy for metastatic disease.

Shepherd FA, Bunn PA, Paz-Ares L.

Am Soc Clin Oncol Educ Book. 2013:339-46. doi: 10.1200/EdBook_AM.2013.33.339. Review.


Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.

Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR.

Cancer. 2013 Jul 1;119(13):2383-90. doi: 10.1002/cncr.28089. Epub 2013 Apr 12.


Characteristics of lung cancers harboring NRAS mutations.

Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W.

Clin Cancer Res. 2013 May 1;19(9):2584-91. doi: 10.1158/1078-0432.CCR-12-3173. Epub 2013 Mar 20.


Volatile fingerprints of cancer specific genetic mutations.

Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA Jr, Hirsch FR, Haick H.

Nanomedicine. 2013 Aug;9(6):758-66. doi: 10.1016/j.nano.2013.01.008. Epub 2013 Feb 18.


Endobronchial miRNAs as biomarkers in lung cancer chemoprevention.

Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR.

Cancer Prev Res (Phila). 2013 Feb;6(2):100-8. doi: 10.1158/1940-6207.CAPR-12-0382. Epub 2012 Dec 26.


Worldwide overview of the current status of lung cancer diagnosis and treatment.

Bunn PA Jr.

Arch Pathol Lab Med. 2012 Dec;136(12):1478-81. doi: 10.5858/arpa.2012-0295-SA. Review.


Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR.

J Thorac Oncol. 2012 Dec;7(12):1807-14. doi: 10.1097/JTO.0b013e3182745948.

Supplemental Content

Support Center